Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Key Laboratory of Glycoconjugate Research Ministry of Health, School of Basic Medical Sciences, Fudan University, Shanghai, China.
J Hematol Oncol. 2018 Apr 4;11(1):50. doi: 10.1186/s13045-018-0595-3.
Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of tumor-related death, so it is urgently needed to discover efficient markers and targets for therapy. β-1,3-N-acetylgalactosaminyltransferase II (B3GALNT2) belongs to the β-1,3-glycosyltransferases (b3GT) family and has been reported to regulate development of both normal and tumor tissues. However, studies on the functions of B3GALNT2 in cancer are quite limited. Here we investigated the potential role of B3GALNT2 in HCC progression.
Western blot, qPCR, and immunohistochemistry assays were performed to quantify the relative expression of B3GALNT2 in HCC. The functions of B3GALNT2 in tumor progression were evaluated in HCC cell lines and nude mice. Metabolomics analysis was applied to detect alternatively expressed small molecules. Enzyme activity assays were employed to determine the tautomerase activity of macrophage inhibitory factor (MIF).
For expression analysis, higher levels of B3GALNT2 were observed in tumor tissues compared with adjacent normal tissues, and upregulation of B3GALNT2 correlated with increased tumor size and worse overall survival. Changing levels of B3GALNT2 did not influence cell viability in vitro but promoted tumor growth via enhancing macrophage recruitment in vivo. Furthermore, acetoacetate was identified as a key molecule in B3GALNT2-mediated macrophage recruitment. Mechanistically, B3GALNT2 downregulated expression of enzymes involved in acetoacetate-related metabolism, and reduction of acetoacetate revived MIF activity, thus promoting macrophage recruitment.
This study evaluated B3GALNT2 as a tumor marker in HCC and revealed functions of B3GALNT2 in metabolic transformation and microenvironmental remodeling in HCC. Mechanistically, B3GALNT2 reduced expression of some metabolic enzymes and thus downregulated levels of secreted acetoacetate. This relieved the activity of MIF and enhanced macrophage recruitment to promote tumor growth.
肝细胞癌 (HCC) 位居第六大常见癌症和第三大肿瘤相关死亡原因,因此迫切需要发现有效的治疗标志物和靶点。β-1,3-N-乙酰半乳糖胺基转移酶 II (B3GALNT2) 属于β-1,3-糖基转移酶 (b3GT) 家族,已被报道调节正常组织和肿瘤组织的发育。然而,关于 B3GALNT2 在癌症中的功能研究相当有限。在这里,我们研究了 B3GALNT2 在 HCC 进展中的潜在作用。
通过 Western blot、qPCR 和免疫组织化学检测 HCC 中 B3GALNT2 的相对表达。在 HCC 细胞系和裸鼠中评估 B3GALNT2 在肿瘤进展中的功能。应用代谢组学分析检测替代表达的小分子。酶活性测定用于测定巨噬细胞抑制因子 (MIF) 的互变异构酶活性。
表达分析显示,肿瘤组织中 B3GALNT2 的水平高于相邻正常组织,B3GALNT2 的上调与肿瘤增大和总体生存率降低相关。B3GALNT2 水平的变化在体外不影响细胞活力,但在体内通过增强巨噬细胞募集促进肿瘤生长。此外,乙酰乙酸被鉴定为 B3GALNT2 介导的巨噬细胞募集中的关键分子。机制上,B3GALNT2 下调与乙酰乙酸相关代谢相关的酶的表达,减少乙酰乙酸恢复 MIF 活性,从而促进巨噬细胞募集。
本研究评估了 B3GALNT2 作为 HCC 的肿瘤标志物,并揭示了 B3GALNT2 在 HCC 代谢转化和微环境重塑中的功能。机制上,B3GALNT2 降低了一些代谢酶的表达,从而降低了分泌的乙酰乙酸水平。这减轻了 MIF 的活性并增强了巨噬细胞募集以促进肿瘤生长。